Assessing the impact of HAART on the incidence of defining and non-defining AIDS cancers among patients with HIV/AIDS: A systematic review  by Cobucci, Ricardo Ney Oliveira et al.
JR
A
i
A
H
R
P
M
J
a
B
b
c
B
d
d
R
h
1ournal of Infection and Public Health (2015) 8, 1—10
EVIEW
ssessing  the  impact  of  HAART  on  the
ncidence  of  deﬁning  and  non-deﬁning
IDS cancers  among  patients  with
IV/AIDS:  A  systematic  review
icardo  Ney  Oliveira  Cobuccia,b,∗,  Paulo  Henrique  Limaa,
ollyana  Carvalho  de  Souzab,  Vanessa  Viana  Costab,
aria  da  Conceic¸ão  de  Mesquita  Cornettad,
osé  Veríssimo  Fernandesc,  Ana  Katherine  Gonc¸alvesd
Center  for  Health  Sciences  of  the  Federal  University  of  Rio  Grande  do  Norte,  Natal,
razil
Department  of  Gynecology  and  Obstetrics  of  the  Potiguar  University,  Natal,  Brazil
Department  of  Biosciences  of  the  Federal  University  of  Rio  Grande  do  Norte,  Natal,
razil
Department  of  Gynecology  and  Obstetrics  of  the  Federal  University  of  Rio  Grande
o Norte,  Natal,  Brazil
eceived  13  February  2014;  received  in  revised  form  27  May  2014;  accepted  24  August  2014
KEYWORDS
Acquired
immunodeﬁciency
syndrome;
Highly  active
antiretroviral  therapy;
Carcinoma;
Summary  After  highly  active  antiretroviral  therapy  (HAART)  became  widespread,
several  studies  demonstrated  changes  in  the  incidence  of  deﬁning  and  non-deﬁning
AIDS  cancers  among  HIV/AIDS  patients.  We  conducted  a  systematic  review  of  obser-
vational  studies  evaluating  the  incidence  of  malignancies  before  and  after  the
introduction  of  HAART  in  people  with  HIV/AIDS.  Eligible  studies  were  searched  up
to  December  2012  in  the  following  databases:  Pubmed,  Embase,  Scielo,  Cancerlit
and  Google  Scholar.  In  this  study,  we  determined  the  cancer  risk  ratio  by  comparing
the  pre-  and  post-HAART  eras.  Twenty-one  relevant  articles  were  found,  involvingIncidence more  than  600,000  people  with  HIV/AIDS  and  10,891  new  cases  of  cancers.  The
risk  for  the  development  of  an  AIDS-deﬁning  cancer  decreased  after  the  introduc-
tion  of  HAART:  Kaposi’s  sarcoma  (RR  =  0.30,  95%  CI:  0.28—0.33)  and  non-Hodgkin’s
lymphoma  (RR  =  0.52,  95%  CI:  0.48—0.56),  in  contrast  to  invasive  cervical  cancer
(RR  =  1.46,  95%  CI:  1.09—1.94).  Among  the  non-AIDS-deﬁning  cancers,  the  overall
risk  increased  after  the  introduction  of  HAART  (RR  =  2.00,  95%  CI:  1.79—2.23).  The
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incidence  of  AIDS-deﬁning  cancers  decreased  and  the  incidence  of  non-AIDS-deﬁning
cancers  increased  after  the  early  use  of  HAART,  probably  due  to  better  control  of  viral
replication,  increased  immunity  and  increased  survival  provided  by  new  drugs.
©  2014  King  Saud  Bin  Abdulaziz  University  for  Health  Sciences.  Published  by  Elsevier
Limited.  All  rights  reserved.
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Introduction
Since  1996,  when  highly  active  antiretroviral  ther-
apy (HAART)  became  widespread  in  North  America,
Europe  and  Australia,  the  mortality  rate  in  HIV-
infected patients  dropped  dramatically,  mainly
because  of  the  decrease  in  the  incidence  of  oppor-
tunistic infections.  In  addition  to  life  expectancy,
the therapy  also  affected  the  epidemiology  of
non-AIDS-deﬁning  cancers  (NADCs)  and  has  an
important  impact  on  the  evolution  of  these  tumors
[1].
Before  HAART,  cancers  were  responsible  for  less
than 10%  of  deaths  among  HIV-infected  patients  [1].
After HAART,  28%  of  deaths  in  this  population  have
been attributed  to  neoplastic  causes  [2],  despite
a function  of  the  increase  in  the  incidence  and
mortality of  NADCs  [4]. However,  it  is  still  not  clear
in the  literature  whether  the  higher  incidence  of
carcinomas  in  the  post-HAART  era  is  only  due  to
the larger  number  of  new  cases  of  NADCs  or  if
there are  other  factors  involved,  such  as  the  longer
life expectancy  afforded  by  HAART  [3].
Some studies  speculate  that  as  HIV  patients  live
longer after  the  introduction  of  HAART,  there  is
a greater  potential  to  develop  cancers  [5]. Other
authors believe  that  the  association  between  dif-
ferent risk  factors,  such  as  HIV-infection  chronicity
and its  probable  oncogenic  role,  may  be  involved
[2].
In fact,  despite  the  advances  in  medicine,  can-
cer is  now  one  of  the  leading  causes  of  death  amongthe substantial  decline  in  the  risk  of  acquiring
AIDS-deﬁning  cancers  (ADCs),  especially  Kaposi’s
sarcoma  (KS)  and  non-Hodgkin’s  lymphoma  (NHL)
[3].  It  is  believed  that  this  phenomenon  occurs  as
p
p
o
datients  who  live  with  HIV  [6]. This  article  aims  to
rovide a systematic  review  to  evaluate  the  impact
f HAART  on  the  incidence  of  deﬁning  and  non-
eﬁning AIDS  cancers.
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Figure  1  Study  selection.
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his  study  adhered  to  the  MOOSE  guidelines  [7].
nclusion criteria
tudies  meeting  the  following  criteria  were
ncluded: (1)  cohort  studies  of  people  with  HIV/AIDS
hat assessed  cancer  incidence  before  and  after  the
ntroduction  of  HAART,  (2)  studies  including  adult
ubjects,  (3)  studies  published  between  2001  and
012 and  (4)  studies  including  data  on  the  cancer
ncidence  in  person-years.
earch and selection of literature
ligible  studies  were  identiﬁed  by  searching  the
ollowing  databases:  Pubmed,  Embase,  Scielo,
ancerlit and  Google  Scholar.  The  studies  were
dentiﬁed  by  a  literature  search  of  the  databases
sing the  following  medical  subject  heading  terms
nd/or text  words:  ‘‘AIDS’’,  ‘‘HIV’’,  ‘‘cancer’’,
‘HAART’’, ‘‘incidence’’  and  ‘‘cohort’’.  The  ref-
rence lists  of  the  identiﬁed  publications  were
eviewed for  additional  pertinent  studies.  No  lan-
uage restrictions  were  imposed.
Three researchers  (PHL,  PCS  and  MCMC)
earched for  articles  published  prior  to  December
012. After  searching  the  databases,  2392  poten-
ially  relevant  HIV/AIDS  papers  were  identiﬁed,
333 of  which  were  excluded:  1929  after  reviewing
he title  and  404  after  reviewing  the  abstract.
hree studies  were  included  after  reviewing  the
eferences.
Thus,  62  papers  met  the  search  criteria  and  were
valuated  using  the  Newcastle-Ottawa  scale  [8]; 35
ere excluded.  The  Newcastle-Ottawa  scale  eval-
ates the  quality  of  cohort  studies;  articles  that
core higher  than  ﬁve  are  considered  to  be  studies
f ‘‘high  methodological  quality’’.  The  scale  was
ndependently  applied  by  two  researchers  (RNOC
nd MCMC),  and  any  discordance  was  solved  by  a
hird researcher  (AKSG).  Six  articles  were  excluded
or repeated  reporting  (Fig.  1).
ata extraction
arious  study  characteristics  were  extracted  from
he original  studies  and  included  in  the  systematic
eview. The  data  included  the  ﬁrst  authors’  last
ames,  the  year  of  publication,  the  country,  the
tudy  design,  the  period  of  follow  up,  the  number
f patients,  the  total  person-years  and  the  num-
er of  cancers  (Table  1).  Cancer  incidence  among
IV/AIDS  patients  in  the  pre-  and  post-HAART
d
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periods  were  abstracted  from  each  study.  Three
lind reviewers  (RNOC,  MCMC  and  AKSG)  used
he inclusion  criteria  to  choose  eligible  articles.
isagreements were  solved  by  means  of  mutual
onsensus.
nalysis
ata  were  entered  in  Review  Manager  (RevMan)  4.2.
his software  allows  the  user  to  enter  protocols,  to
omplete reviews,  including  text,  characteristics  of
he studies,  comparison  tables,  and  study  data,  and
o perform  meta-analyses  of  the  data  entered.
With the  incidence  in  person-years,  we  deter-
ined the  risk  ratio  for  each  studied  malignancy
sing ﬁxed  and  random  effects  models  and  testing
or the  heterogeneity  of  effects  using  the  Chi-
quared test  in  RevMan  4.2.
esults
e  found  21  relevant  articles  involving  more  than
ix hundred  thousand  HIV/AIDS  patients,  who  con-
ributed more  than  two  million  person-years  of
ollow-up  and  who  were  diagnosed  with  10,891  new
ases of  cancers.  The  design  features  of  the  chosen
tudies  are  indicated  in  Table  1.
Regarding  the  ADCs,  the  beginning  of  HAART
ecreased the  risk  to  develop  KS  (RR  =  0.30,
5% CI:  0.28—0.33)  and  NHL  (RR  =  0.52,  95%  CI:
.48—0.56)  when  compared  with  the  pre-HAART
eriod (Figs.  2  and  3). In  contrast  to  KS and  NHL,  we
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Table  1  Cohort  study  design  features  of  cancer  risk  in  HIV/AIDS  patients.
Study,  year  (reference)  Country  Study  type  Period  of
follow-up
Number  of
patients
Total
number  of
person-
years
Number  of
cancers
Dorrucci  et  al.,  2001  [27] Italy  Cohort  1981—1998  483  3364  6
Bower  et  al.,  2003  [29] UK  RLa 1986—2001 8400  22,694  11
Bower  et  al.,  2004  [30] UK  Cohort  1984—2003 8640  40,126  26
Hessol  et  al.,  2004  [31]  USA  RLa 1994—2001  1554  7909  41
Biggar  et  al.,  2006  [15]  USA  RLa 1980—2002  317,428  477,368  173
D’Souza  et  al.,  2008  [32]  USA  Cohort  1984—2006  6972  100,000  69
Franceschi  et  al.,  2008  [33]  Switzerland  Cohort  1984—2006  12,959  73,412  597
Polesel  et  al.,  2008  [34]  Switzerland  Cohort  1984—2006  12,959  75,222  429
Engels  et  al.,  2008  [35]  USA  Cohort  1991—2002  57,350  186,157  871
Crum-Cianﬂone  et  al.,  2009  [4]  USA  Cohort  1984—2006  4498  33,486  446
Clifford  et  al.,  2009  [36]  Switzerland  Cohort  1984—2007  14,606  84,611  47
Dal  Maso  et  al.,  2009  [43]  Italy  RLa 1986—2004  21,951  101,668  1995
Leewen  et  al.,  2009  [20]  Australia  Cohort  1982—2004  37,407  311,496  2283
Powles  et  al.,  2009  [41]  UK  Cohort  1983—2007  11,112  71,687  156
Buchacz  et  al.,  2010  [37] USA  Cohort  1994—2007  8070  3000  16
Crum-Cianﬂone,  2010  [39] USA  Cohort  1985—2008  4506  37,806  66
Franceschi  et  al.,  2010  [42] Switzerland  RLa 1985—2006  9429  53,715  1460
Seaberg  et  al.,  2010  [40] USA  Cohort  1984—2007  6972  77,320  933
Besson  et  al.,  2011  [38] France  RLa 1993—1998  80,000  230,173  900
Kirk  et  al.,  2001  [24] Europe  Cohort  1994—2000  8471  26,764  222
Franzetti  et  al.,  2012  [10] Italy  Cohort  1985—2011  5924  50,990  144
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found  that  the  risk  of  developing  invasive  cervical
cancer (RR  =  1.46,  95%  CI:  1.09—1.94)  increased
after the  introduction  of  HAART  (Fig.  4).
In the  articles  that  included  data  on  non-
Hodgkin’s lymphoma,  we  found  that  the  introduc-
tion of  HAART  decreased  the  rates  of  non-Hodgkin’s
lymphoma, especially  the  risk  of  primary  brain
lymphoma (RR  =  0.24,  95%  CI:  0.20—0.30).  The
risk of  acquiring  diffuse  large  B-cell  lymphoma
and Burkitt’s  lymphoma,  the  two  most  com-
mons systemic  NHL  subtypes  among  patients  with
HIV/AIDS,  also  decreased  signiﬁcantly  (RR  = 0.44,
1
l
(
Figure  2  Incidence  rates  for  Kaposi’s  sarcoma  in  the  pre-  an
in  the  pre-HAART  compared  with  the  post-HAART  era.5%  CI:  0.40—0.49  and  RR  = 0.44,  95%  CI:  0.27—0.73,
espectively).
The overall  risk  of  developing  NADCs  increased
fter the  introduction  of  HAART  (RR  =  2.00,  95%  CI:
.79—2.23),  as  shown  in  Fig.  5.  However,  among  the
ancers studied,  we  found  a signiﬁcant  risk  increase
n a group  of  six  malignancies:  anus  (RR  =  4.28,
5% CI:  3.25—5.64),  colorectal  (RR  =  1.91,  95%  CI:
.03—3.52),  Hodgkin’s  lymphoma  (RR  =  1.40,  95%  CI:
.16—1.69), liver  (RR  =  3.58,  95%  CI:  2.57—4.99),
ung (RR  =  2.19,  95%  CI:  1.54—3.11)  and  prostate
RR = 2.57,  95%  CI:  1.49—4.44).
d  post-HAART  eras  and  the  risk  ratios  of  incidence  rates
HAART  impact  on  cancer  incidence  among  HIV  patients  5
Figure  3  Incidence  rates  for  non-Hodgkin’s  lymphoma  in  the  pre-  and  post-HAART  and  the  risk  ratios  of  incidence
rates  in  the  pre-HAART  compared  with  the  post-HAART  era.
Figure  4  Incidence  rates  for  invasive  cervical  cancer  in  the  pre-  and  post-HAART  eras  and  the  risk  ratios  of  incidence
rates  in  the  pre-HAART  compared  with  the  post-HAART  era.
Figure  5  Incidence  rates  for  non-AIDS-deﬁning  cancers  in  the  pre-  and  post-HAART  eras  and  the  risk  ratios  of  incidence
rates  in  the  pre-HAART  compared  with  the  post-HAART  era.
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However,  we  did  not  ﬁnd  a  statistically  signiﬁ-
cant increase  or  decrease  in  the  development  of
the following  NADC  types  after  the  initiation  of
HAART:  bladder  (RR  =  1.88,  95%  CI:  0.59—6.00),  CNS
(RR = 1.81,  95%  CI:  0.86—3.85),  kidney  (RR  =  1.79,
95% CI:  0.72—4.44),  leukemia  (RR  =  0.84,  95%
CI: 0.44—1.60),  melanoma  (RR  =  1.08,  95%
CI: 0.71—1.65)  and  testis  (RR  =  0.84,  95%  CI:
0.38—1.89).
Discussion
Non-AIDS-deﬁning cancers (NADCs)
Several  theories  attempt  to  explain  the  increas-
ing importance  of  NADCs  among  HIV-infected
patients.  Although  some  studies  have  demon-
strated a  direct  relationship  between  HAART  and
increased  incidence  of  NADCs  [4], it  is  more  likely
that antiretroviral  therapy  indirectly  affects  the
epidemiology  of  these  cancers  because  HAART
increases the  life  expectancy  of  people  living  with
HIV, thus  allowing  the  emergence  of  these  carcino-
mas [4].
Another  possibility  is  that  the  genomic  instabil-
ity caused  by  zidovudine  may  contribute  to  the
increased  incidence  of  certain  types  of  NADCs.
The ﬁrst  nucleoside  reverse  transcriptase  inhibitors
(NRTIs)  approved  for  the  therapy  of  HIV  is
incorporated into  DNA,  causes  mutations  in  the
hypoxanthine-guanine  phosphoribosyl-transferase
(HPRT)  and  thymidine  kinase  (TK)  genes,  and
induces micronuclei,  chromosomal  aberrations,
sister chromatid  exchange,  shortened  telomeres,
and other  genotoxic  effects  in  cultured  cells  [9].
Anal cancer
There  is  a  proven  association  between  anogenital
cancers and  infection  by  human  papilloma  virus
(HPV),  and  we  also  know  that  patients  living  with
HIV have  a  higher  incidence  of  HPV  infection,  espe-
cially of  high-risk  strains  [10]. We  found  a  fourfold
increase  in  the  risk  for  developing  anal  cancer  in
the post-HAART  era  (RR:  4.28,  95%  CI:  3.25—5.64).
Our ﬁnding  was  similar  to  the  results  found  by
Legarth  et  al.  in  2013  (RR:  77.9,  95%  CI:  36.2—167.7)
[11].  This  fact  can  be  explained  partly  by  the  fact
that the  use  of  HAART  does  not  reduce  the  inci-
dence of  anogenital  cancer  precursor  lesions  and  it
does not  seem  able  to  eliminate  HPV  infection  [10].
Furthermore,  the  recommendations  of  performing
screening for  anal  cancer  and  its  precursors  in  the
population  with  HIV  can  lead  to  an  increase  in  the
t
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umber  of  diagnoses  [12]. Recently,  a multicenter
tudy showed  that  the  use  of  HAART  was  associated
ith a  lower  prevalence  of  anal  intraepithelial  neo-
lasia (AIN)  and  a lower  prevalence  of  HPV  infection
13]. However,  this  study  has  some  limitations  that
hould be  highlighted,  including  its  cross-sectional
esign. Additionally,  the  article  does  not  address
he effect  of  HAART  on  high-grade  anal  intraepithe-
ial neoplasia  (HGAIN)  speciﬁcally,  as  the  size  of  the
tudy was  limited  and  only  a  small  proportion  of
hose with  AIN  had  HGAIN  [14].
odgkin’s lymphoma
odgkin’s  lymphoma  (HL)  is  a common  malignancy
mong patients  with  AIDS,  congenital  immunode-
ciency syndromes  or  those  under  immunosup-
ressive drug  regimens.  This  fact  suggests  that
mmunosuppression  is  directly  related  to  the  patho-
enesis of  HL;  however,  the  relationship  is  much
ore complex  and  multifactorial  [15].  We  found
n increased  risk  for  developing  HL  after  HAART
RR: 1.40,  95%  CI:  1.16—1.69)  that  was  similar  to
he standardized  incidence  ratio  (SIR)  found  by
lifford et  al.  in  2005  (pre-HAART  SIR  = 17.3  com-
ared to  post-HAART  SIR  =  36.2)  [16]  and  Herida
t al.  in  2003  (pre-HAART  SIR  22.75  compared  to
ost-HAART  SIR  = 31.66)  [17]. In  addition  to  the  sub-
tantial increase  in  the  age  of  the  population  living
ith HIV  after  the  introduction  of  HAART  (from  34.2
ears to  42.8  years)  [16], the  increased  incidence
s related  to  immune  reconstitution:  it  is  known
hat the  incidence  of  HL  decreases  with  severe
mmunosuppression  and  increases  with  moderate
mmunosuppression  [15].  It  is  also  known  that  HL
s strongly  associated  with  Epstein—Barr  virus  (EBV)
nfection  and  that  immune  reconstitution  increases
he stimulation  of  B  cells,  thereby  increasing  the
umber  of  lymphocytes  infected  with  EBV  [15].
iver cancer
n  general,  the  incidence  of  liver  cancer  is increased
n patients  with  HIV/AIDS.  Some  studies  suggest
hat this  difference  may  result  from  a greater
revalence of  infection  by  hepatitis  B  virus  (HBV),
nd especially  hepatitis  C  virus  (HCV)  [18]. The  co-
nfection of  HIV  and  HBV  or  HCV  seems  to  increase
he risk  of  cirrhosis,  end-stage  renal  disease  and
epatocellular  carcinoma.  Our  statistical  analysis
ound that  the  risk  for  developing  liver  cancer  after
AART increased  more  than  three  times  compared
o the  pre-HAART  risk  (RR:  3.58,  95%  CI:  2.57—4.99),
imilar  to  what  was  found  by  Sahasrabuddhe  et  al.
n 2012,  (RR  =  2.50,  95%  CI:  1.70—3.70)  [18].  The
ain reason  for  the  higher  risk  is  the  increase  in
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urvival  of  people  living  with  HIV/AIDS  after  the
ntroduction  of  HAART;  in  addition,  it  is  suspected
hat the  hepatotoxicity  of  HAART  may  worsen  the
arcinogenic  effect  of  hepatitis  B  and  C  [18].
ung cancer
any  studies  indicate  that  lung  cancer  is the  most
ommon  NADC  in  the  HIV-infected  population,  in
oth the  pre-  and  post-HAART  eras.  As  smoking  is
he main  risk  factor  for  the  development  of  lung
ancer, we  established  the  relationship  between
he increased  incidence  of  this  tumor  with  the
ighest rate  of  smoking  in  the  HIV-infected  popula-
ion; in  fact,  35—70%  of  people  living  with  HIV/AIDS
moke, while  only  20%  of  the  general  population  are
mokers [19].  However,  other  factors  also  appear  to
e related  to  the  increased  incidence  of  lung  cancer
n these  patients  because  the  risk  remains  high  even
fter correcting  for  smoking  status  [10].  Although
ome studies  do  not  show  a  statistically  signiﬁcant
ncrease in  the  risk  of  developing  lung  cancer  after
AART [10,20],  our  study  found  a  doubling  of  the
re-HAART  era  risk  in  the  post-HAART  era  (RR:  2.19,
5% CI:  1.54—3.11),  and  this  result  is  similar  to  what
as found  by  Polesel  et  al.  in  2010  (RR:  1.8,  95%  CI:
.00—3.2) [21].  The  increased  risk  may  be  explained
n part  by  the  long  period  from  the  acquisition  of
IV until  the  diagnosis  for  lung  cancer  (11  years
n average  in  the  post-HAART  era).  Thus,  studies
n the  pre-HAART  era,  when  the  life  expectancy  of
he HIV-infected  population  was  much  lower  than
hat of  the  post-HAART  era,  made  no  diagnoses  of
ung cancer  simply  because  the  patients  died  from
ther causes  ﬁrst,  mainly  opportunistic  infections
nd AIDS-deﬁning  cancers  [19].
rostate cancer
lthough  we  found  an  increased  incidence  of
rostate cancer  in  the  post-HAART  era  (RR:  2.57,
5% CI:  1.49—4.44),  very  few  of  the  published  stud-
es included  this  outcome,  so  we  cannot  clearly
etermine the  direction  of  this  neoplasia  in  HIV-
ositive  patients.  Moreover,  among  the  few  articles
hat address  prostate  cancer,  the  samples  studied
re small  and  thus  not  able  to  detect  signiﬁcant
ifferences [10].  In  2009,  Silberstein  et  al.  [22]
uggested  that  HAART  may  be  a  protective  factor
gainst  prostate  cancer.  However,  in  2008,  Pan-
anowitz  et  al.  [23]  showed  that  in  a cohort  study,
2% of men  diagnosed  with  prostate  cancer  were
eceiving  HAART.  We  know  that  the  risk  of  devel-
ping prostate  cancer  is associated  with  the  age
nd origin  of  the  patients;  moreover,  the  presence
r absence  of  a  screening  program  substantially
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lters  the  incidence  of  this  neoplasia.  Many  articles
10,22,23]  showed  that  the  incidence  of  prostate
ancer in  patients  living  with  HIV/AIDS  may  be
qual, lower  or  even  higher  than  that  of  the  general
opulation,  which  highlights  the  need  to  perform
ore studies  before  deﬁnitive  conclusions  can  be
eached.
IDS-deﬁning cancers (ADCs)
aposi’s  Sarcoma  (KS)
ince the  advent  of  HAART,  there  has  been  a dra-
atic and  continuing  decline  in  the  incidence  of
S [20], especially  in  the  late  post-HAART  period
ompared to  the  early  post-HAART  [19].  As  in  the
tudies of  Cianﬂone  et  al.  (RR:  12.32,  95%  CI:
.24—12.44) [4]  and  van  Leewen  et  al.  (RR:  0.21,
5% CI:  0.18—0.24)  [20], we  found  a reduction  in
he risk  for  developing  KS  after  the  initiation  of
AART  (RR:  0.30,  95%  CI:  0.28—12.33).  Despite  the
act that  the  restoration  of  the  immune  system
an lead  to  a transient  increase  in  KS  lesions,  a
anifestation  of  immune  reconstitution  syndrome,
AART  reduces  the  incidence  of  KS  by  various  fac-
ors, including  the  reduction  of  HIV  replication,
hus improving  the  immune  responses  against  HHV8
nd the  direct  anti-angiogenic  activity  of  some  pro-
ease inhibitors.  Recent  studies  suggest  that  the
ncidence  of  KS  in  people  with  HIV  is  now  stabi-
ized at  a  much  lower  rate,  although  the  rate  is
till substantially  high  when  compared  to  that  of
he general  population  [12].
on-Hodgkin’s  Lymphoma  (NHL)
imilar to  the  rates  of  KS,  we  found  a reduction  in
he risk  for  developing  NHL  after  the  introduction
f HAART  (RR  =  0.52,  95%  CI:  0.48—0.56).  Although
ome studies  show  that  the  decline  in  the  incidence
s stabilizing,  others  show  that  the  decline  con-
inues even  when  comparing  the  early  post-HAART
eriods to  the  late  post-HAART  era,  suggesting  that
n the  future,  the  difference  in  risk  between  the
eneral  population  and  HIV-infected  population  will
isappear [12,20]. The  reduction  in  the  risk  of  NHL
s directly  related  to  the  increased  CD4  count;
owever, for  Burkitt’s  lymphoma,  that  is  not  true
ecause this  type  of  NHL  occurs  when  the  CD4  count
s relatively  high  (>200  cells/mm3) [24].  Even  so,  we
ound a reduction  in  the  risk  for  Burkitt’s  lymphoma
ince the  introduction  of  HAART  (RR:  0.44,  95%  CI:
.27—0.73),  as  well  as  in  the  risks  for  primary  lym-
homa of  the  central  nervous  system  (RR:  0.24,  95%
I: 0.20—0.30)  and  diffuse  large  B-cell  lymphoma
RR: 0.44,  95%  CI:  0.27—0.73).
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Invasive  cervical  cancer  (ICC)
Unlike other  AIDS-deﬁning  malignancies,  the  inci-
dence of  invasive  cervical  cancer  does  not  seem
to have  diminished  after  the  advent  of  HAART
[25].  Cohort  studies  with  individual  patient  data
on HAART  use  have  produced  conﬂicting  results
with a  reduced  risk  associated  with  HAART  reported
in some  but  not  all  studies  [12]. We  found  an
increased risk  for  developing  invasive  cervical  can-
cer after  the  introduction  of  HAART  (RR:  1.46,
95% CI:  1.09—1.94),  similar  to  what  was  found
by Gingues  and  Gill  [26]  in  2006.  The  increased
incidence for  developing  invasive  cervical  cancer,
even after  the  advent  of  HAART,  may  have  several
explanations, including  the  fact  that  the  female
population with  HIV  is  living  longer,  that  antiretrovi-
ral therapy  does  not  prevent  the  appearance  of  ICC
as it  was  thought  to  previously,  or  even  that  there  is
an inadequate  screening  program  for  women  living
with HIV  [27]. Thus,  it  is  unclear  how  the  immune
reconstitution  induced  by  HAART  affects  the  lesions
induced  by  HPV;  more  research  is  needed  to  estab-
lish a  secure  association  [28].
When comparing  the  data  between  these  stud-
ies, some  limitations  in  the  source  data  must  be
considered.  In  the  included  studies,  most  reports
included  person-years  from  the  5  years  before
the onset  of  AIDS,  but  others  included  only  the
post-AIDS period,  and  the  duration  of  the  post-
AIDS follow-up  period  varied.  This  may  explain
the heterogeneity  among  the  studies  included  in
this systematic  review.  Because  immune  deﬁciency
varies  considerably  during  the  natural  history  of  HIV
infection and  is  also  affected  by  treatment,  the
degree  of  immune  deﬁciency  probably  varied  across
the HIV/AIDS  studies.  Finally,  some  studies  did  not
report data  covering  all  cancer  types.  Nonetheless,
there was  no  demonstrable  publication  bias.
Conclusion
Arguably,  HAART  contributed  to  the  increased  sur-
vival of  people  living  with  HIV  by  providing  greater
control of  viral  replication  and  increased  immunity.
This  somewhat  explains  the  reduction  of  new  cases
of AIDS-deﬁning  carcinomas  such  as  KS  and  NHL  in
the post-HAART  era  because  the  incidence  of  these
cancers  decreases  in  the  immunocompetent  popu-
lation.
In addition,  the  increased  survival  allowed  the
detection  of  malignant  tumors,  as  NADCs  (liver,  lung
and prostate)  were  greatly  undiagnosed  before  the
introduction  of  HAART  because  these  carcinomas
arising in  HIV-infected  individuals  were  uncommon
in the  pre-HAART  era.R.N.O.  Cobucci  et  al.
Moreover,  other  factors  are  associated  with
he lower  or  higher  incidence  of  cancers  follow-
ng the  introduction  of  HAART.  Some  are  already
ell deﬁned,  such  as  the  hepatotoxicity  of  HAART
hat may  predispose  patients  to  the  emergence
f hepatic  carcinoma  and  immune  reconstitu-
ion, which  increases  the  number  of  lymphocytes
nfected with  EBV.  However,  it is  not  completely
nown how  these  factors  increase  the  carcinomas  of
he lung,  prostate  and  cervix  in  the  post-HAART  era,
nd larger  studies  are  needed  to  elucidate  these
nteractions.
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